Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Byrna Technologies Inc (BYRN) vs Celestica Inc (CLS) Price & Performance

Byrna Technologies IncTrade
Celestica IncTrade

Price performance (Past 24H)

Key statistics

Byrna Technologies Inc vs Celestica Inc — how do they compare? Byrna Technologies Inc trades at $4.37 (market cap $106.74M), while Celestica Inc trades at $328.38 (market cap $39.16B). The key difference: Celestica Inc is far larger — about 366.9× Byrna Technologies Inc's market cap, and Celestica Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.

BYRNCLS
Market Cap
$106.74M$39.16B
Sector
TechnologyTechnology
52-Week High
$27.63$472.40
52-Week Low
$3.18$181.34
Enterprise Value
$98.35M$39.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Byrna Technologies Inc

No Aura AI signal available yet.

Celestica Inc

CLS trades at $327.15, up 3.99% in 24 hours, with a bearish technical signal but strong fundamentals including a 52.69% ROE and Q2 2026 EPS of $2.54 beating estimates. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, though this may cause near-term dilution.

The outlook is positive with analyst consensus at Buy (64.29%) and a $466.50 price target, driven by AI demand and partnerships. Risks include equity dilution and premium valuation, but growth catalysts from hyperscaler investments support long-term upside.

Returns comparison

Trailing returns across standard periods

About Byrna Technologies Inc

Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.

Read more on BYRN

About Celestica Inc

Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.

Read more on CLS